ライフサイエンスコーパス: intracranial hypertension

1 ence of contraindications (i.e., preexisting intracranial hypertension).

2 headache, anemia, fatigue, hypertension, and intracranial hypertension.

3 pinal fluid of some patients with idiopathic intracranial hypertension.

4 lay a role in the pathogenesis of idiopathic intracranial hypertension.

5 ate coma as outlined above failed to control intracranial hypertension.

6 25-30 torr (3.33-4.00 kPa) was used to treat intracranial hypertension.

7 atients develop cerebral injury secondary to intracranial hypertension.

8 fer from a high frequency rate of idiopathic intracranial hypertension.

9 after transplantation, primarily because of intracranial hypertension.

10 racranial pressure in 91.7% of patients with intracranial hypertension.

11 rease intracranial pressure in patients with intracranial hypertension.

12 cranial hypotension is more rare than benign intracranial hypertension.

13 id replacement are probable causes of benign intracranial hypertension.

14 centers had a protocol for the treatment of intracranial hypertension.

15 d/or midazolam for the treatment of episodic intracranial hypertension.

16 generally present with signs and symptoms of intracranial hypertension.

17 ension burden when administered for episodic intracranial hypertension.

18 ry correlated with Deltaarea under the curve-intracranial hypertension.

19 aumatic brain injury, hypothermia can reduce intracranial hypertension.

20 ve drugs, and medical/surgical therapies for intracranial hypertension.

21 had low sensitivity (11%-42%) for detecting intracranial hypertension.

22 luded tolerability, systemic hypotension and intracranial hypertension.

23 for identifying critically ill patients with intracranial hypertension.

24 sion, mass effect, infection, hemorrhage, or intracranial hypertension.

25 therapy in refractory status epilepticus and intracranial hypertension.

26 and scored intensity of therapies targeting intracranial hypertension.

27 arious forms of hydrocephalus and ideopathic intracranial hypertension.

28 nificantly in the population not affected by intracranial hypertension.

29 nial findings similar to those in idiopathic intracranial hypertension.

30 th severe subarachnoid hemorrhage not having intracranial hypertension.

31 regarding the pathophysiology of idiopathic intracranial hypertension.

32 presence and severity of papilledema, due to intracranial hypertension.

33 with low to intermediate risk of developing intracranial hypertension.

34 optic neuropathy (NAION), conditions without intracranial hypertension.

35 establish the first-line medical therapy for intracranial hypertension.

36 uropathy (AION), and 25 with papilledema and intracranial hypertension.

37 <100 beats/min plus mannitol (250 mg/kg) for intracranial hypertension.

38 blood pressure >100 mm Hg plus mannitol for intracranial hypertension.

39 all aggregate mean Deltaarea under the curve-intracranial hypertension = +17 mm Hg x min, 95% CI, 0-3

40 21-day mortality was higher in patients with intracranial hypertension (43% vs 23%, p = 0.05).

41 Pseudotumor cerebri (also called idiopathic intracranial hypertension), a known complication of seve

42 nts during the surgical management of severe intracranial hypertension after traumatic brain injury (

43 Nine patients with uncontrolled intracranial hypertension and ALF who fulfilled the crit

44 Non-invasive detection of intracranial hypertension and assessment of cerebral per

45 Intracranial hypertension and cerebral edema are known c

46 d with a risk of brain injury resulting from intracranial hypertension and cerebral hypoperfusion.

47 All the patients had intracranial hypertension and cerebral oedema.

48 ns for understanding glaucoma and idiopathic intracranial hypertension and could help explain visual

49 tanding of the pathophysiology of idiopathic intracranial hypertension and glaucoma.

50 mon-and often the presenting-symptom of both intracranial hypertension and intracranial hypotension s

51 Hyperammonemia has been associated with intracranial hypertension and mortality in patients with

52 f jugular venous desaturation and refractory intracranial hypertension and on long-term neurologic ou

53 Hypothermia is also effective in mitigating intracranial hypertension and reducing brain edema.

54 s in diagnosis or misdiagnosis of idiopathic intracranial hypertension and spontaneous intracranial h

55 physiology and the mechanisms of idiopathic intracranial hypertension and spontaneous intracranial h

56 To improve the diagnosis of idiopathic intracranial hypertension and spontaneous intracranial h

57 If left untreated, idiopathic intracranial hypertension and spontaneous intracranial h

58 s provide accurate and timely predictions of intracranial hypertension and tissue hypoxia crises in p

59 and unconsciousness used to treat refractory intracranial hypertension and to manage treatment-resist

60 ts with clinical or radiographic evidence of intracranial hypertension and/or cerebral swelling were

61 monitoring modalities used, the treatment of intracranial hypertension, and general care of severely

62 ated with the development of cerebral edema, intracranial hypertension, and secondary neuronal injury

63 to use corticosteroids for the treatment of intracranial hypertension as a result of head trauma.

64 patients with severe acute brain trauma and intracranial hypertension associated with compromised ce

65 ata suggest that in FHF patients who develop intracranial hypertension before OLT, dissection of the

66 oxically, we observed an overall increase in intracranial hypertension burden following drug administ

67 f fentanyl and midazolam fails to reduce the intracranial hypertension burden when administered for e

68 cranial pressure can lead to the reversal of intracranial hypertension, but in most patients cerebral

69 sed intracranial pressure and had documented intracranial hypertension, cerebral oedema, or both.

70 8) months in the hydrocephalus and suspected intracranial hypertension cohort (60% female), and 59.7

71 saline, have been used for the management of intracranial hypertension crises and as a measure to pre

72 In severe cases of cerebral edema, intracranial hypertension develops and leads to brain de

73 al pressure monitored patients received more intracranial hypertension-directed therapies (mannitol,

74 ebrospinal fluid of patients with idiopathic intracranial hypertension, elevated intracranial pressur

75 for central pontine myelinolysis and rebound intracranial hypertension exists with uncontrolled admin

76 plots was calculated to represent cumulative intracranial hypertension exposure: area under the curve

77 re often used as second-tier strategies when intracranial hypertension following severe traumatic bra

78 craniectomy for the treatment of refractory intracranial hypertension following traumatic brain inju

79 (mean age = 25 yr) who developed refractory intracranial hypertension following traumatic brain inju

80 our of the eight patients with pretransplant intracranial hypertension had six episodes of ICP increa

81 Decompressive craniectomy in refractory intracranial hypertension has been associated with poor

82 The primary goal of identifying and treating intracranial hypertension has given way to a focus on se

83 diatric traumatic brain injury before severe intracranial hypertension has the potential to be neurop

84 ugh the demographics of pediatric idiopathic intracranial hypertension have been well described, the

85 However, development of intracranial hypertension (ICH) may be affected by facto

86 ociated with hepatic encephalopathy (HE) and intracranial hypertension (ICH).

87 The ability to detect intracranial hypertension (ICP >/= 20 mm Hg) was highest

88 of induced hypernatremia on the incidence of intracranial hypertension (IH) in patients with ALF.

89 c management and prevention and treatment of intracranial hypertension (IHTN).

90 the population-based incidence of idiopathic intracranial hypertension (IIH) and to determine if it m

91 ociated with papilledema owing to idiopathic intracranial hypertension (IIH) at presentation.

92 Idiopathic intracranial hypertension (IIH) can present with severe

93 Idiopathic intracranial hypertension (IIH) is a condition in which

94 Idiopathic intracranial hypertension (IIH) is a potentially blindin

95 Idiopathic intracranial hypertension (IIH) is a rare but important

96 enesis and treatment paradigm for idiopathic intracranial hypertension (IIH) is controversial.

97 thalmological findings similar to idiopathic intracranial hypertension (IIH) patients.

98 ohorts of untreated patients with idiopathic intracranial hypertension (IIH) to characterize the dise

99 olamide is commonly used to treat idiopathic intracranial hypertension (IIH), but there is insufficie

100 ed MR venography in patients with idiopathic intracranial hypertension (IIH).

101 ual loss is the main morbidity of idiopathic intracranial hypertension (IIH).

102 in the diagnosis and treatment of idiopathic intracranial hypertension (IIH).

103 with the development of vasogenic edema and intracranial hypertension in a number of neurological di

104 o standard therapy, as firstline therapy for intracranial hypertension in certain intracranial pathol

105 A similar proportion died due to refractory intracranial hypertension in each group (abusive head tr

106 hypothermia could be tested for treatment of intracranial hypertension in fulminant hepatic failure.

107 terature and literature on the management of intracranial hypertension in non-acute liver failure pat

108 Intracranial hypertension in patients with acute liver f

109 ults, hypothermia reduces cerebral edema and intracranial hypertension in patients with acute liver f

110 ulted in worsening of cerebral hyperemia and intracranial hypertension in patients with ALF and sever

111 Increased CBF contributes to intracranial hypertension in patients with ALF.

112 Hypothermia reduces intracranial hypertension in patients with traumatic bra

113 racterize the occurrence and significance of intracranial hypertension in severe intraventricular hem

114 t patients during surgical decompression for intracranial hypertension in the acute phase after traum

115 The management of benign intracranial hypertension includes, symptomatic headache

116 ffect, and time after injury as a covariate, intracranial hypertension increased after administration

117 The mean Deltaarea under the curve-intracranial hypertension increased significantly after

118 tailed information, 44 (51%) had evidence of intracranial hypertension (intracranial pressure > 25 mm

119 Idiopathic intracranial hypertension is a disease of unknown aetiol

120 Idiopathic intracranial hypertension is a disorder characterised by

121 Benign intracranial hypertension is a rare syndrome of increase

122 tions of giant cell arteritis and idiopathic intracranial hypertension is classified herein according

123 Idiopathic intracranial hypertension is common in obese women and c

124 monitored patients with acute liver failure, intracranial hypertension is commonly observed.

125 The incidence of idiopathic intracranial hypertension is expected to increase as rat

126 The effectiveness of treatments that address intracranial hypertension is generally assessed by measu

127 severe cerebrovascular disease and impending intracranial hypertension is safe and might reduce the f

128 Benign intracranial hypertension is though to be caused by cere

129 ral blood patch, a rebound and self-limiting intracranial hypertension may sometimes develop.

130 h acute liver failure (ALF) and uncontrolled intracranial hypertension, moderate hypothermia (32 degr

131 of patients with hydrocephalus and suspected intracranial hypertension (n = 5), and the negative cont

132 These episodes of intracranial hypertension occurred during failing liver

133 Benign intracranial hypertension often has no abnormal imaging

134 Pediatric intracranial hypertension patients may be followed with

135 with multiple sclerosis (MS), (2) idiopathic intracranial hypertension (pseudotumor cerebri), (3) non

136 55 mmol/L may be considered in patients with intracranial hypertension refractory to mannitol.

137 tcomes in patients with refractory traumatic intracranial hypertension remains unclear.

138 ients with hemorrhagic shock, as therapy for intracranial hypertension resistant to standard therapy,

139 s with traumatic brain injury and refractory intracranial hypertension resulted in lower mortality an

140 arious forms of hydrocephalus and idiopathic intracranial hypertension.SIGNIFICANCE STATEMENT Effecti

141 ues are used to look for secondary causes of intracranial hypertension such as cerebral venous sinus

142 admitted to our Emergency Department with an intracranial hypertension syndrome.

143 asis of hypothermia in patients with ALF and intracranial hypertension that is unresponsive to standa

144 Investigators of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) report

145 o month 12 in participants of the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).

146 The Idiopathic Intracranial Hypertension Treatment Trial represents the

147 Intracranial hypertension was suspected on physical exam

148 ressure above 20 mm Hg (area under the curve-intracranial hypertension) was calculated in 15-minute e

149 nistration epochs (Deltaarea under the curve-intracranial hypertension), was calculated for all occur